Keywords
hyperglycaemia
diabetes mellitus type 1
diabetes mellitus type 2
other types of diabetes
How to Cite
Abstract
Diabetes is a chronic metabolic disorder with a rapidly growing incidence worldwide. It is currently classified into two main types, type 1 and type 2 diabetes, based on status of the autoantibodies directed at the β-cell. However, it does not reflect the complexity of diabetes and the broad spectrum of the clinical manifestations, particularly in type 2.
In this review we present the evolution of the World Health Organization (WHO) classification of diabetes, with a focus on newly introduced categories – hybrid forms of diabetes and unclassified diabetes. We compare the WHO diabetes subgroups with the American Diabetes Association (ADA) approach to this issue. Since the current classification systems do not reflect all the factors leading to hyperglycaemia in type 2 diabetes, we present novel approach to phenotyping diabetes in adults based on six variables (age at diagnosis, body mass index [BMI], C-peptide based homeostasis model assessments of β-cell function and insulin resistance, haemoglobin A1c and glutamic acid decarboxylase antibodies [GADA] status) which allowed to distinguish five replicable groups of patients in Swedish cohort with different clinical presentations.
The understanding heterogeneity of diabetes helps to classify the patients more adequately, but none of classifications is optimal. Including combination of genetic, metabolomic and clinical factors into classification schemas will pave the way towards personalized medicine in diabetes and will presumably result in more effective treatment of the patients.
References
(1) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387(10027):1513-30. DOI:10.1016/S0140-6736(16)00618-8.
(2) Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Vol. 58, Diabetologia 2015; 443-55. DOI:10.1007/s00125-014-3462-y.
(3) Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Vol. 383, The Lancet 2014; 1084-94. DOI:10.1016/S0140-6736(13)62219-9.
(4) Farmer A, Fox R. Diagnosis, classification, and treatment of diabetes. Vol. 343, BMJ (Online) 2011. DOI:10.1136/bmj.d3319.
(5) Diabetes mellitus. Report of a WHO Expert Committee.
Geneva: World Health Organization 1965.
(6) WHO Expert Committee on Diabetes Mellitus. Second Report. Technical report Series 646. Geneva, World Health Organization 1980.
(7) World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization 1999.
(8) World Health Organization (WHO) 2019. Classification of Diabetes Mellitus. Geneva: April. https://www.who.int/publicationsdetail/classification-of-diabetes-mellitus.
(9) Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 2017; 66:241-255. DOI:10.2337/db16-0806.
(10) Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab 2007; 92:2403-7. DOI:10.1210/jc.2007-0339.
(11) Erlich H, Valdes AM, Noble J, Carlson JA, Varney M. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk. Diabetes 2008 Apr; 57(4):1084-1092. DOI:10.2337/db07-1331.
(12) Farsanin SF, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review BMJ Open 2017; 7(7):e016587. DOI:10.1136/bmjopen-2017-016587.
(13) Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, et al. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab 2008; 34:529-532, DOI:10.1016/j.diabet.2008.05.003.
(14) Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. J Diabetes Investig 2019 Sep; 10(5):1158-1164. DOI:10.1111/jdi.13091.
(15) Kahn SE, Cooper ME, del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014; 383:1068-1083. DOI:10.1016/S0140-6736(13)62154-6.
(16) Nadeau KJ, et al. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities Diabetes Care 2016 Sep; 39(9):1635-1642. DOI:10.2337/dc16-1066.
(17) Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008; 57:1433-1437. DOI:10.2337/db07-0299.
(18) Lebovitz HE, Banerji MA. Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity. Curr Diab Rep 2018; 18(11):120. DOI:10.1007/s11892-018-1075-4.
(19) Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009; 10(Suppl. 12): 33-42.
(20) Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diab Res Clin Pract 2014; 103:341-63.
(21) Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6(5):361-9. DOI:10.1016/S2213-8587(18)30051-2.
(22) Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 2019; 7(6):442-51. DOI:10.1016/S2213-8587(19)30087-7.
(23) Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. J Clin Endocrinol Metab 2016; 101(12):4500-11. DOI:10.1210/jc.2016-2466.
(24) Ardon O, Procter M, Tvrdik T, Longo N, Mao R. Sequencing analysis of insulin receptor defects and detection of two novel mutations in INSR gene. Mol Genet Metab Reports 2014; 1(1):71-84. DOI:10.1016/j.ymgmr.2013.12.006.
(25) Gnudi L, Coward RJM, Long DA. Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Vol. 27, Trends in Endocrinology and Metabolism 2016; 820-30. DOI:10.1016/ j.tem.2016.07.002.
(26) Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733):2215-22. DOI:10.1016/S0140-6736(10)60484-9.
(27) Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010; 59(2):479-85. DOI:10.2337/db09-1169.
(28) Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5. DOI:10.1038/ncomms5309.
(29) Li L, Cheng WY, Glicksberg BS, Gottesman O, Tamler R, Chen R, Bottinger EP, Dudley JT. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med 2015; 7(311). DOI:10.1126/scitranslmed.aaa9364.
(30) Merino J, Florez JC. Precision medicine in diabetes: an opportunity for clinical translation. Vol. 1411, Annals of the New York Academy of Sciences 2018; 140-52. DOI:10.1111/nyas.13588.
(31) Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: Moving from information to knowledge. Vol. 58, Diabetes 2009; 2429-43. DOI:10.2337/db09-0580.
(32) Skupien J, Malecki MT. Expanding diabetes classification – new subtypes and therapeutic options. Clinical Diabetology 2007; 8:1-12.
(33) Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020; 43(Suppl.1):14-31. DOI:10.2337/dc20-S002.
(34) Nowak-Oczkowska A, Robak-Kontna K, Wyrębska-Ruge J, et al. Maturity Onset Diabetes of the Young. Diabetology Practice 2018; 17, 89-96.
(35) Nair VV, Chapla A, Arulappan N, Thomas N. Molecular diagnosis of maturity onset diabetes of the young in India. Indian J Endocr Metab 2013; 17:430-41. DOI:10.4103/2230-8210. 111636.
(36) Stoffel M. Maturity-Onset Diabetes of the Young: Molecular Genetics, Clinical Manifestations, and Therapy. In: Portesky L, editors. Principles of Diabetes Mellitus. 2nd ed. New York: Springer 2009; 221-232.
(37) Aguilar-Bryan L, Bryan J. Neonatal Diabetes Mellitus. Endocrine Reviews 2008; 29(3):265-291. DOI:10.1210/er.2007 -0029.
(38) Maassen JA, Kadowaki T. Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetology 1996; 39:375-382. DOI:10.1007/BF00400668.
(39) Rojek A, Niedziela M. Insulin receptor defect as a cause of Rabson-Mendenhall and other rare genetic insulin resistance. Pediatr Endocrinol 2010; 16, 205-212.
(40) Grunberger G, Alfonso B. Syndromes of Extreme Insulin Resistance. In: Portesky L, editors. Principles of Diabetes Mellitus. 2nd ed. New York: Springer 2009; 259-279.
(41) Harris AG, Letourneau LR, Greeley SAW. Monogenic diabetes: the impact of making the right diagnosis. Curr Opin Pediatr 2018; 30(4):558-567. DOI:10.1097/MOP.0000000000000643.
(42) Skupien J, Klupa T, Malecki MT. Genetic background of type 2 diabetes. Clinical Diabetology 2006; 7(2):67-77.
(43) McCarthy MI. Genomics, Type 2 Diabetes, and Obesity. N Engl J Med 2010; 363(24):2339-2350. DOI:10.1056/NEJMra0906948.
(44) Brown K, Shulinder AR. Genetics of Type 2 Diabetes: From Candidate Genes to Genome-Wide Association Analysis. In: Portesky L, editors. Principles of Diabetes Mellitus. 2nd ed. New York: Springer; 2009. 147-156.
(45) Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38:1964-1974. DOI:10.2337/dc15-1419.
(46) Moran A, Pillay K, Becker D at al. ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2018; 19(Suppl. 27):64-67. DOI:10.1111/pedi.12732.
(47) Wallia A, Illuri V, Molitch ME. Diabetes care after transplant: definitions, risk factors, and clinical management. Med Clin North Am 2016; 100:535-550. DOI:10.1016/j.mcna.2016.01.005.
(48) Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol 2019 Mar; 15(3):172-188. DOI:10.1038/s41574-018-0137-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.